GENFLEET-B (02595) announced its annual results for the period ending December 31, 2025. The company reported revenue of 130 million yuan, representing a year-on-year increase of 24.42%. Research and development costs were 282 million yuan, a decrease of 15.01% compared to the previous year. The net loss amounted to 17.95 billion yuan, widening by 164.82% year-on-year.

The company has successfully completed multiple licensing agreements both domestically and internationally over the years, maintaining steady operating income. For the 2025 fiscal year, operating revenue exceeded 130 million yuan, marking a growth of nearly 25% compared to the prior year. Furthermore, the company maintains ample cash reserves, with cash and bank balances surpassing 2 billion yuan as of the end of 2025.

GENFLEET-B was listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2025. Since 2022, among all biotech companies listed under Chapter 18A of the listing rules, the company achieved the highest total proceeds raised in its initial public offering (amounting to $268 million after the full exercise of the over-allotment option) and secured the largest cornerstone investment subscription ($100 million). It is also the only Chapter 18A listed company that had a commercialized Class 1 innovative drug generating out-licensing revenue at the time of its listing.

Within six months of its listing, the company was included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs. It also became a constituent stock of the Hang Seng Index series, including the Hang Seng Composite Index.